POWERFUL BLEED PROTECTION WITH THE ONLY FIX FDA APPROVED FOR UP TO 14-DAY DOSING*
*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month without spontaneous bleeding.
†Zero median annualized spontaneous bleeding rate (AsBR) when dosed at 7 or 14 days in clinical trials.
‡Steady-state levels measured FIX at trough levels before each infusion every four weeks until week 92 at 7-day prophylaxis and
week 104 at 14-day prophylaxis. FIX levels were 13% when dosed every 14 days.
RESOURCES FOR YOU AND YOUR PATIENTS
CSL Behring is committed to providing treatments and supportive services that make a meaningful difference in the lives of people with bleeding disorders.
Resources available to help your patients get the treatment they need for hemophilia B include:
- A free 30-day trial of IDELVION
- Co-pay assistance for IDELVION prescriptions and refills
- Reimbursement and access support
References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Data on file. Available from CSL Behring as DOF IDL-002.